HIGH POINT, N.C.--(BUSINESS WIRE)--vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company committed to the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, announced today that company Chief Medical Officer, Dr. Larry Altstiel, MD, PhD, will speak on a panel at Neuro Advance Boston hosted by Harvard Medical School. Dr. Altstiel will participate on the panel “Novel Approaches to Alzheimer’s Disease,” from 9:30 to 10:10am on October 5th. Dr. Altstiel will focus on the novel mechanism of action behind vTv’s lead investigational drug candidate called azeliragon, which is currently being studied in a Phase 3 trial for the treatment of mild Alzheimer’s disease.
